by Admin | Feb 23, 2021 | Portfolio News
•Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion) •The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies CHENGDU,...
by Admin | Feb 17, 2021 | Portfolio News
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced the appointment of seasoned financial executive, Tamra J. Adams, as the Company’s chief financial officer (CFO) effective March 1, 2021. Ms. Adams fills a newly...
by Admin | Feb 3, 2021 | Portfolio News
2021-02-01 22:57 The Board of Directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 1st February 2021, the Group through a wholly-owned subsidiary of the...
by Admin | Feb 1, 2021 | Portfolio News
2021-02-01 14:00 三叶草生物制药有限公司今天宣布，其“S-三聚体”重组蛋白亚单位新冠候选疫苗在与佐剂联合使用下，I 期临床研究中显示出良好的安全性和免疫原性，该积极结果发表于同行评审期刊《柳叶刀》。 三叶草生物的 “S-三聚体”新冠候选疫苗在与佐剂联合使用下，I 期临床研究中显示出良好的安全性和耐受性，并诱导出强烈的中和免疫应答。 三叶草生物计划在2021年上半年启动全球II/III期临床试验，并有望在2021年年中发布其疫苗有效性的中期结果。 中国成都2021年2月1日 /美通社/ —...
by Admin | Feb 1, 2021 | Portfolio News
2021-02-01 14:00 Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially...
by Admin | Jan 25, 2021 | Portfolio News
Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide...
by Admin | Dec 22, 2020 | Portfolio News
Today Eccogene announces that it has completed a new series financing of more than 100 million RMB, co-led by Delos Capital and Oriza Seed, with participation from new investors HuaGai Capital, Tsing Song Capital and existing investor Sinopharm Capital. The raised...
by Admin | Dec 21, 2020 | Portfolio News
December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is...
by Admin | Dec 4, 2020 | Portfolio News
Clover Biopharmaceuticals is set to start a phase 2/3 clinical trial of a COVID-19 vaccine featuring an adjuvant from GlaxoSmithKline. The Chinese vaccine developer committed to starting the study later this month after reviewing data on 150 participants in a phase 1...
by Admin | Dec 1, 2020 | Portfolio News
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) —...
